Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Nichols FY profits slip despite modest revenue growth

(Sharecast News) - Soft drinks group Nichols said on Tuesday that both operating and pre-tax profits had fallen in FY24 despite reporting a modest uptick in group revenues. Nichols said group revenues were up 1.2% in FY24, while operating profits slipped 3.6% and pre-tax profits fell 0.9% to £21.5m and £24.0m, respectively. Underlying earnings were down 4.3% at £23.5m, while cash and equivalents fell 19.9% to £53.7m, and free cash flow dropped 14.9% to £17.8m.

On an adjusted basis, operating profits were up 14.6% at £28.9m, and pre-tax profits improved 15.6% to £31.4m. Adjusted underlying earnings were up 11.7% at £30.8m.

However, Nichols still proposed a final dividend of 17.1p per share, up 9.6% per year, taking its total dividend to 32.0p for FY24, up 13.4% year-on-year.

Nichols added that trading has been "positive" so far in FY25 and that it anticipates a further strengthening across the year as it "remains confident" in its ability to deliver further strategic progress and a continued strong financial performance.

As of 0955 GMT, Nichols shares were down 2.29% at 1,280.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.